Targeting advanced glycation with pharmaceutical agents: where are we now? (Q38890348)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

review article

1 reference

title

Targeting advanced glycation with pharmaceutical agents: where are we now? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Danielle J Borg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

9 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

published in

Glycoconjugate Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

653-670

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27392438%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10719-016-9691-1

18 March 2020

exact match

0 references

cites work

Pathways of the Maillard reaction under physiological conditions

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation endproducts in food and their effects on health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Current therapeutic interventions in the glycation pathway: evidence from clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Nonenzymatic browning in vivo: possible process for aging of long-lived proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Protein glycation, diabetes, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Level of an advanced glycated end product is genetically determined: a study of normal twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Genetic analysis of advanced glycation end products in the DHS MIND study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

N-ε-fructosyllysine and N-ε-carboxymethyllysine, but not lysinoalanine, are available for absorption after simulated gastrointestinal digestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Role of advanced glycation end products in cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Scavenger receptors for oxidized and glycated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation end-products: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Post-Glucose Load Plasma α-Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Iridoids are natural glycation inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Nitric oxide synthases: structure, function and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Chelating activity of advanced glycation end-product inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Novel inhibitors of advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy: a detective story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

AGE-breaker ALT-711 plus insulin could restore erectile function in streptozocin-induced type 1 diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Glucose-mediated cross-linking of collagen in rat tendon and skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The unique reactivity of N-phenacyl-derived thiazolium salts toward α-dicarbonyl compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Alagebrium chloride protects the heart against oxidative stress in aging rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Aminoguanidine downregulates expression of cytokine-induced Fas and inducible nitric oxide synthase but not cytokine-enhanced surface antigens of rat islet cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Advanced glycation end products are direct modulators of β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-016-9691-1

Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose

21 January 2018

1 reference

12 December 2020

Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications

1 reference

12 December 2020

Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment

1 reference

12 December 2020

Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure

1 reference

12 December 2020

Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.

1 reference

12 December 2020

In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways

1 reference

12 December 2020

Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications

1 reference

12 December 2020

Effect of High-Dose Thiamine and Pyridoxine on Advanced Glycation End Products and Other Oxidative Stress Markers in Hemodialysis Patients: A Randomized Placebo-Controlled Study

1 reference

12 December 2020

Pharmacokinetics of aminoguanidine administration and effects on the diabetes frequency in nonobese diabetic mice

1 reference

12 December 2020

Improvement by aminoguanidine of insulin secretion from pancreatic islets grafted to syngeneic diabetic rats

1 reference

12 December 2020

Rapid hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links

1 reference

12 December 2020

Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats

1 reference

12 December 2020

Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice

1 reference

12 December 2020

Effects of aminoguanidine on rat pancreatic islets in culture and on the pancreatic islet blood flow of anaesthetized rats

1 reference

12 December 2020

Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats

1 reference

12 December 2020

Targeted reduction of advanced glycation improves renal function in obesity

1 reference

12 December 2020

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

1 reference

12 December 2020

Diets rich in Maillard reaction products affect protein digestibility in adolescent males aged 11-14 y.

1 reference

12 December 2020

Maternal plasma advanced glycation end products concentrations in response to oral 50-gram glucose load in mid-pregnancy: a pilot study

1 reference

12 December 2020

Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions

1 reference

12 December 2020

Mechanisms for the formation of glycoxidation products in end-stage renal disease

1 reference

12 December 2020

Bioavailability Assessment of the Lipophilic Benfotiamine as Compared to a Water-Soluble Thiamin Derivative

1 reference

12 December 2020

Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats

1 reference

12 December 2020

The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis

1 reference

12 December 2020

Metformin inhibition of glycation processes

1 reference

12 December 2020

Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats

1 reference

12 December 2020

Effects of aminoguanidine on insulin release from pancreatic islets

1 reference

12 December 2020

Nitric oxide synthases: structure, function and inhibition

1 reference

12 December 2020

Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats

1 reference

12 December 2020

Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine

1 reference

12 December 2020

Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins

1 reference

12 December 2020

Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals

1 reference

12 December 2020

Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs

1 reference

12 December 2020

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

1 reference

12 December 2020

Intervention against the Maillard reaction in vivo

1 reference

12 December 2020

Effects of aminoguanidine on glucagon and insulin release from rat pancreatic islet

1 reference

12 December 2020

Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation

1 reference

12 December 2020

Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation

1 reference

12 December 2020

Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice

1 reference

12 December 2020

Nitric oxide synthesis and the effect of aminoguanidine and NG-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat

1 reference

12 December 2020

2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage

1 reference

12 December 2020